Introduction
Approximately 15% of lung cancer patients have a pleural effusion at the time of initial diagnosis, and 50% develop a pleural effusion later in their courses (Anderson et al., 1974; Memon and Zawadzki, 1981) . Patients with malignant pleural effusion (MPE) have a short life expectancy and are difficult to manage clinically (Naito et al., 1997; Sugiura et al., 1997) . Therefore, a novel approach to improve the management of MPE is needed; however, the underlying mechanism of MPE formation is not fully understood.
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is a pivotal angiogenic factor mediating developmental, physiological, and pathological neovascularization (Carmeliet et al., 1996; Ferrara et al., 1996) . Vascular endothelial growth factor is also a potent agent in inducing vascular permeability, which facilitates the extravasation of proteins and the formation of ascites (Senger et al., 1983) . Vascular endothelial growth factor is also implicated in the increase of vascular permeability and the production of pleural effusion of pleurae in experimental animal models. In humans, MPE commonly accompanies ADCLC (Hoffman et al., 2000) . Among patients with MPE-associated ADCLC, the VEGF level in pleural fluid was found to be approximately 10 times higher than that in serum (Zebrowski et al., 1999) . Therefore, VEGF/VPF could be a key regulator in MPE production.
Signal transducer and activator of transcription (STAT) proteins are latent cytoplasmic transcription factors that become activated in response to growth factors and cytokines. Activated STATs form homoor heterodimers and translocate to the nucleus, bind to the promoter region of specific target genes, and regulate gene transcription (Yu and Jove, 2004) . Signal transducer and activator of transcription proteins play an important role in signaling pathways critical to normal cellular processes, including the immune function, proliferation, survival, differentiation, and development (Buettner et al., 2002; Levy and Darnell, 2002) . Constitutive activation of STATs, in particular Stat3, is found in a number of primary human tumors and cancer cell lines (Turkson, 2004) , including lung cancer (Fernandes et al., 1999) . Interleukin (IL)-6 is a pleiotropic cytokine that not only regulates immune and inflammatory responses but also regulates cell growth in many tumors (Kishimoto et al., 1992; Hutchins and Steel, 1994; Siegsmund et al., 1994; Okamoto et al., 1997) . Interleukin-6 is required in the control of cell proliferation in a subset of human NSCLC cell lines (Bihl et al., 1998) , because GP130/ JAK/Stat3 is one of the major pathways for mediating IL-6 signaling and IL-6 participates in the upregulation of VEGF via Stat3 activation in cervical cancer cells (Wei et al., 2003) . Moreover, Stat3 binds VEGF promoter directly when regulating VEGF expression (Niu et al., 2002) . We were, therefore, interested in investigating whether IL-6-induced Stat3 activation and the subsequent upregulation of VEGF mediates the generation of MPE in ADCLC.
In this study, autocrine IL-6-mediated Stat3 activation and upregulation of VEGF are implicated to the generation of malignant effusion in human ADCLC cell lines and animal models. We also found higher expression of IL-6 and VEGF in the pleural fluids of patients with ADCLC and of constitutively activated Stat3 in tumor cells infiltrated in the pleurae. The data suggest an important role for the IL-6/Stat3 pathway in the pathogenesis of ADCLC and MPE.
Results
Stat3 is constitutively activated in human lung cancer cell lines To characterize Stat3 expression and activation status in vitro, a panel of seven human lung cancer cell lines was examined using Western blot analysis with general Stat3 antibody to detect Stat3 protein expression, or with pStat3-Y705-specific antibody to detect active-form Stat3, respectively. The human embryonic kidney cells -293T, which have very low endogenous Stat3 level, were used as negative control (Figure 1a , lane 9). The lysate from 293T cells containing an active-form Stat3 (Stat3C) plasmid and treated with 10 ng/ml IL-6 for 30 min was used as a positive control ( Figure 1a , lane 8). Stat3 is commonly activated in human lung cancer cell lines (Figure 1a ). The amount of Stat3 and phosphorylated Stat3 varied between these cells. The levels of Stat3 phosphorylation were highest in H157 and H1435 cells (lanes 2 and 5; upper panel) and lowest in H1650 cells (lane 6; upper panel) . The extent of Stat3 phosphorylation does not correlate with the amount of intracellular Stat3. For example, the H1650 cell line expressed a high level of Stat3 protein but had only modest Stat3 phosphorylation (lane 6; upper two panels). On the contrary, the H460 cell line (lane 3; upper two panels) expressed a low level of Stat3 protein but had a high pStat3-Y705 level. The findings of Stat3 activation in lung cancer cell lines are compatible with other reports (Song et al., 2003) .
Stat3 was constitutively activated in tumor cells that infiltrated the pleurae of patients with malignant pleural effusion-associated adenocarcinoma cell lung cancer To investigate whether what we observed in vitro also appeared in vivo, we analysed, using immunohistochemical stains probed with pStat3-Y705-specific antibody, ADCLC cells that had infiltrated the pleurae of ADCLC patients with MPE. A positive stain in the nucleus was taken as an indicator of Stat3 activation (Figure 1b) . Of 114 tumor samples analysed, we had 42 from patients with stage I/II ADCLC, 35 from patients with stage III ADCLC without MPE, and 37 from patients with ADCLC with MPE (stage IIIb or IV). The positive rate was 24, 14, and 54%, respectively (Table 1) . The differences between MPE-associated ADCLC vs Figure 1 Constitutive activation of Stat3 in human lung cancer cell lines and tumor tissues. (a) Expression and phosphorylation levels of Stat3 in human NSCLC cell lines and 293T cells were examined using Western blot. Cell lysates containing 70 mg of protein were resolved in a 10% SDS-polyacrylamide gel, and the derived blot was probed with anti-phosphotyrosine-705-specific Stat3 antibody, general Stat3 antibody, and b-actin antibody, respectively. The lysate from 293 T cells was used as negative control (NC) and from 293T cells containing an active-form Stat3 (Stat3C) plasmid and treated with 10 ng/ml IL-6 for 30 min was used as positive control (PC). (b) Immunohistochemical detection of activated pStat3-Y705 protein in an MPE-associated ADCLC tissue. An intense and widely spread nuclear staining for phosphorStat3 ( Â 400 magnification) in a pleural metastatic tumor tissue was detected (black arrow). Figure 2a, lane 2) . Notably, the phosphorylation of Stat3 recovered spontaneously 3 h after starvation, and gradually returned to its original level (Figure 2a , lanes 3-5). The results in the H1355 human lung ADCLC cell line were similar (Figure 2b ), but the recovery of Stat3 activation was quicker in H1355 cells. The spontaneous recovery of Stat3 activation in ADCLC cells in serumdeprived condition suggested the presence of an autocrine mechanism. To confirm this possibility, the medium in which PC14PE6/AS2 cells were serumdeprived for 24 h was collected and applied to PC14PE6/AS2 cells that had been cultured in serumdeprived medium for 30 min. After treating cells with the conditioned medium for 5, 30, and 60 min, respectively, cell lysates were prepared and analysed for Stat3 activation. Phosphorylation of Stat3 was induced in serum-starved PC14PE6/AS2 cells within 5 min in conditioned medium (Figure 2c , lanes 5-7) but not in 10% FBS-containing medium ( Figure 2c , lanes 2-4). This finding strongly suggests a secretory factor in the conditioned medium that induced Stat3 activation in ADCLC cells. To identify the possible autocrine factor responsible for Stat3 activation, we screened several candidates previously implicated, IL-6, epidermal growth factor (EGF), hepatocyte growth factor (HGF), and insulinlike growth factor (IGF)-1 (Levy and Darnell, 2002) . In PC14PE6/AS2 cells deprived of serum for 30 min, IL-6 stimulated Stat3 activation (Figure 2a and b, lanes 6 and 7; upper panels), but EGF, HGF, and IGF-1 did not (data not shown). Therefore, we hypothesized that IL-6 was the likely choice. To confirm this, enzyme-linked immunosorbent assay (ELISA) assays were performed to detect the expression levels of IL-6 in the medium of PC14PE6/AS2 cells after serum deprivation at the indicated time points. The IL-6 level was lowest 30 min after serum deprivation but increased gradually to a high level after 24-48 h (Figure 2d ). The time course of IL-6 secretion was compatible with Stat3 activation in PC14PE6/AS2 cells after serum deprivation.
Autocrine interleukin-6-mediated Stat3 activation in PC14PE6/AS2 cells occurs via the interleukin-6-receptor (gp130)/JAK pathway Because the gp130/JAK pathway mediates IL-6-induced Stat3 activation, we used gp130 antibody to see whether it blocked autocrine IL-6-mediated activation of Stat3. The constitutively activated Stat3 in serum-starved PC14PE6/AS2 (Figure 3a ) and H1355 ( Figure 3b ) cells was dose-dependently reduced after treatment with gp130 antibody. The addition of AG490, a specific Jak inhibitor, prevented autocrine IL-6-mediated Jak 2 phosphrylation as well as Stat3 activation at different time points (Figure 3c ). In contrast to the findings in another human lung adenocarcinoma A549 cells (Song et al., 2003) , where constitutive pStat3-Y705 is mainly regulated by Src, the Src kinase inhibitor PP1 had no inhibitory effect on Stat3 activation in PC14PE6/AS2 cells ( Figure 3d ). The p-Src status in PC14PE6/AS2 cells was also blocked by another Src inhibitor-PP2 but the p-Stat3-Y705 status remains stable. The Src control inhibitor-PP3 did not inhibit p-Src and had no effect on p-Stat3 expression (Supplementary Data). All these findings taken together mean that the constitutive activation of Stat3 PC14PE6/AS2 cells is mediated by the IL-6/gp130/Jak pathway.
Activated Stat3 mediated the generation of experimental malignant ascites and pleural effusion Intravenous injection of PC14PE6 cells into nude mice yields numerous lung lesions whose cells invade the pleura and produce PE containing a high level of VEGF (Yano et al., 2000a, b) . PC14PE6/AS2 cells were established from malignant ascites generated in SCID mice by inoculating the peritoneal cavity with PC14PE6 cells. Subsequent experiments in our laboratory demonstrated that PC14PE6/AS2 cells produced malignant ascites in nude mice when injected intraperitoneally, and lung metastases and MPE when injected intravenously.
To understand how activated Stat3 proteins in PC14PE6/AS2 cells contribute to the generation of malignant effusions, we established PC14PE6/AS2 cells stably expressing dominant-negative Stat3 by transfecting them with plasmids containing S3D or S3F. The dominant-negative effect of the S3D and S3F mutants was based on their inactivation of the DNA-binding domain and of tyrosine phosphorylation, respectively. Two cell clones -S3D-8 and S3D-9 -were selected and their expression of S3D was confirmed using Western blot probed with an HA-specific antibody ( Figure 4a , upper panel). One cell clone that expressed S3F and showed markedly decreased tyrosine-phosphorylated Stat3 was selected ( Figure 4b , lower panel). Two S3D clones (S3D-8 and S3D-9) also showed inferior Stat3 transcription activity compared to the vector-transfected control (Vec) (Figure 4b ).
In the ascites animal model, no malignant ascites were formed in mice injected with S3D-8 (0/5), S3D-9 (0/5), or S3F cells (0/5); however, nine of 10 mice in which vector control (Vec) cells were injected developed a considerable amount of malignant ascites (range: 0-3.45 ml; median: 1.47 ml) (Figure 4c and d). Although no ascites were found in mice injected with Stat3-negative cells, scattered tumors in the peritoneal cavity were found in both groups of mice injected with Stat3-negative and -positive cells (data not shown). Next, we injected 1 Â 10 6 Vec, S3D-8, S3D-9, or S3F cells into the tail veins of nude mice. The incidence of lung metastasis in mice injected with Vec cells (3/5) was not significantly higher than that in mice injected with S3D-8 (2/5), S3D-9 (3/5), or S3F (0/5) cells. However, the number of lung metastatic lesions was significantly higher in mice injected with Vec cells than in mice injected with S3D-8, S3D-9, or S3F cells (Po0.01) ( Table 2) . None of the mice injected with S3D-8, S3D-9, or S3F cells developed MPE, but three of five mice given an intravenous injection of Vec cells developed MPE (median: 0.24 ml; range: 0.15-0.3 ml) ( Table 2 ). Stat3 deactivation in PC14PE6/AS2 cells reduced tumor-cell-associated VEGF expression, angiogenesis, and vascular permeability The blocking of Stat3 activation in S3D-8 and S3F cells was associated with a decline in VEGF mRNA (Figure 5a) . A chromatin immunoprecipitation (ChIP) assay of PC14PE6/AS2 cells, carried out to confirm that Stat3 upregulates VEGF expression by directly binding to its promoter, PC14PE6/AS2, detected VEGF promoter in DNA bound with Stat3 ( Figure 5b ). In addition to the lower expression of VEGF mRNA, immunohistochemical analysis showed that the expression of VEGF protein in tumors from S3F cells was ) were injected intravenously (i.v.) into nude mice as described in Materials and methods. The experiment was terminated on day 47, and the mice development of lung lesions and PE were evaluated. *Po0.01 as compared to control group (Vec). lower than that of Vec cells (Figure 5c ). Tumors generated by S3D cells provided similar findings (data not shown). These results provide strong evidence that activated Stat3 transcriptionally upregulates VEGF expression in PC14PE6/AS2 cells.
Because upregulation of VEGF expression is frequently associated with prominent angiogenesis, we performed immunohistochemical staining with anti-CD31 antibody to study the microvessel density (MVD) in tumors ( Figure 6a ). As expected, tumors from S3D-8 and S3D-9 cells expressed less MVD than tumors from Vec cells (Po0.01; both) (Figure 6b) .
Vascular endothelial growth factor is also known as vascular permeability factor (VPF). Its permeabilityinducing effect has been implicated in the generation of malignant effusions (Dvorak et al., 1995) . To understand whether activated Stat3-upregulated VEGF can induce hyper-permeability of vessels, we performed the in vivo permeability assay (Miles assay). Nude mice were intravenously injected with 0.5% Evans blue dye, which binds to endogenous albumin as a tracer. After 10 min, conditioned medium from S3D-8, S3D-9, or Vec cells was intradermally injected into mice. After 30 min, the mice were killed and their skins were carefully removed.
The extent of dye leakage from vessels was measured. The areas of dye leakage induced by conditioned medium from S3D-8 and S3D-9 cells were smaller than the leakage area from Vec cells (Figure 6c and d) . Collectively, the results indicate that VEGF produced by PC14PE6/AS2 cells is biologically active, and that downregulation of VEGF in PC14PE6/AS2 cells by inhibiting Stat3 activation can reduce vascular permeability.
Levels of cytokine interleukin-6 and vascular endothelial growth factor increased in malignant pleural effusion of patients with adenocarcinoma cell lung cancer We demonstrated that Stat3 was commonly activated in the tumor cells of ADCLC patients with MPE. To examine whether Stat3 activation might be induced by IL-6 and whether Stat3 activation result in VEGF upregulation in patients, ELISA was used to measure the levels of IL-6 and VEGF in the malignant pleural effusion of patients with ADCLC and of those with congestive heart failure (CHF). Pleural fluids from two different cohorts of patients were used to detect IL-6 and VEGF expression. There were 32 patients with The number of CD31-positive vessels (red-brown staining denoted by black arrows) was scored for each field. The values in the graph represent the average number of blood vessels in the five selected sections for each cell type. (c) Biologic activity of VEGF secreted by Vec, S3D-8, or S3D-9 tumor cells on vascular permeability was measured using the Miles assay. Serum-free culture supernatants of tumor cells were harvested as test samples. Nude mice were intravenously injected with Evans blue dye. After 10 min, 50 ml of serum-free medium (SF) and test samples (from Vec, S3D-8, or S3D-9 cells) were injected into the dermis of mice. After 30 min, the subdermis was harvested and photographed. The dye leakage areas were marked by dashed black circles. (d) The areas of dye leakage were calculated for each injection site (n ¼ 4); bars, 7s.d.
ADCLC and 44 with CHF, respectively, in the first cohort for IL-6 detection. And there were 23 patients with ADCLC and 12 with CHF, respectively, in the second cohort for VEGF detection. Interleukin-6 levels in malignant pleural effusions of patients with ADCLC were significantly higher than those of patients with CHF (2435774802 vs 26757270.7 pg/ml) (Po0.0001) (Figure 7a ). The same was true of VEGF levels (16467387.4 vs 199.2764.07 pg/ml) (Po0.0001) (Figure 7b ). Although the evidence is indirect, our data support the assumption that IL-6 activates Stat3 and then upregulates VEGF, which leads to the generation of malignant pleural effusion in ADCLC patients.
Discussion
We found that autocrine IL-6 activated Stat3 in lung adenocarcinoma cell lines. Overexpression of dominantnegative Stat3 in the human lung adenocarcinoma cell PC14PE6/AS2 reduced its expression of VEGF, induction of microvessel density and vascular permeability, ability for lung metastasis, and formation of malignant ascites and pleural effusion.
Stat3 activation has been reported in various kinds of human cancers and cell lines (Buettner et al., 2002) as well as in human lung cancer cell lines (Fernandes et al., 1999; Song et al., 2003) and human lung cancer tissues (Seki et al., 2004) . We have also demonstrated that constitutively activated Stat3 exists in many other human lung cancer cell lines. The level of activated Stat3 does not correlate well with the endogenous Stat3 expression in these cells, indicating that Stat3 activation relies more on the modulation than the amount of protein. The constitutive levels of the pStat3-Y705 detected in the PC14PE6/AS2 cells in the manuscript were variable, which was because of different exposure time of Western blot rather than the inconsistency of the experiments itself. When the basal levels of pStat3-Y705 were normalized with total Stat3 protein, the average ratio of the constitutive levels of pStat3-Y705 to total Stat3 protein is 0.71 (0.70 in Figure 1a , lane 7; 0.70 in Figure 3a , lane 1; and 0.73 in Figure 4a Vec); the average ratio of the pStat3-Y705 levels (in 0.5 h serumdeprived condition) to total Stat3 protein is 0.11 (0.10 in Figure 2a , lane 2 and 0.11 in Figure 2a , lane 6; and 0.13 in Figure 2c, lane 1) . Therefore, the expression of the basal level of pStat3-Y705 was actually consistent in different experiments. In human lung cancer tissues, we found a statistically insignificant difference in the activation of Stat3 in 24 and 14% of patients with stage I/II and stage III ADCLC. Interestingly, a higher incidence (54%) of Stat3 activation was found in patients with stage IIIb/IV MPE-associated ADCLC. The differences of Stat3 activation between MPEassociated ADCLC (stage IIIb/IV) and stage I/II or stage III ADCLC were statistically significant (P ¼ 0.0101 and P ¼ 0.0005, respectively). The MPEassociated ADCLC data suggest that Stat3 activation may facilitate ADCLC invading the pleurae and inducing MPE formation. Constitutively activated Stat3 has been observed in another human lung adenocarcinoma cell line, A549. In A549 cells, the activation of Stat3 is mediated primarily by Src kinase, which is downstream of EGFR, c-MET, and IL-6 signals (Song et al., 2003) . However, in PC14PE6/AS2 cells, Stat3 activation is principally mediated by IL-6/Jak signals, because treating PC14PE6/AS2 cells with EGF, HGF, and IGF-1 did not activate Stat3, and autocrine-IL-6-induced Stat3 activation was blocked by AG490 (a Jak inhibitor) but not by PP1 or PP2 (the Src inhibitors). Therefore, Stat3 activation is differentially regulated in different cancer cells. Inhibition of Stat3 activation in A549 cells resulted in cellular apoptosis (Song et al., 2003) , but PC14PE6/AS2 cells remained healthy while their Stat3 DNA-binding activity was blocked by dominant-negative Stat3 (S3D). The maintenance of viability of AS2/SD-8 and -9 cells provide us opportunities to investigate other biologic functions regulated by Stat3.
We detected elevation of IL-6 in the MPE of lung cancer patients, compared with that in effusions from CHF patients, a finding that agrees with other reports Figure 7 Interleukin-6 and VEGF were highly expressed in malignant pleural effusion of patients with ADCLC. (a) Interleukin-6 expression in patients with malignant (ADCLC) and nonmalignant (CHF; congestive heart failure) pleural effusion was detected using ELISA. (b) Vascular endothelial growth factor expression in patients with malignant (ADCLC) and nonmalignant (CHF) pleural effusion was detected using ELISA. Thick black line, mean; *, difference of mean values between MPE group and CHF groups was statistically significant (both Po0.0001; Mann-Whitney test). (Yokoyama et al., 1992; Hoheisel et al., 1998; Alexandrakis et al., 2000; Yamaguchi et al., 2000) . The source of pleural IL-6 could be malignant cells, mesothelial cells, lymphocytes, or macrophages. In the present study, we demonstrated that human ADCLC cells generate IL-6 autocrinely. Taking this together with the finding of Yamaguchi et al. (2000) that ADCLC and other pleural cells produce IL-6, we conclude that the IL-6 in MPE of ADCLC patients is at least partially secreted from ADCLC cells.
Vascular endothelial growth factor is a strong inducer of angiogenesis and vascular permeability. Various kinds of tumor cells, including NSCLC cells, secrete VEGF (Takayama et al., 2000) . Elevated VEGF has been found in human MPE as well as in malignant ascites (Dvorak et al., 1995) . In a previous study (Yano et al., 2000b ) using the parental cell line (PC14PE6) of PC14PE6/AS2, treatment of mice with VEGF receptor inhibitor decreased the generation of MPE. In human cervical tumor cells, IL-6 upregulated VEGF and promoted angiogenesis via Stat3 signaling (Wei et al., 2003) . In PC14PE6/AS2 cells, VEGF expression is also induced by autocrine IL-6-mediated Stat3 activation. The activated Stat3 binds to VEGF promoter directly and then induces VEGF transcription. Elevated VEGF in PC14PE6/AS2 cells induces angiogenesis and high vascular permeability. The increased leakage of plasma proteins and fluids will then produce pleural effusion or ascites. Blocking Stat3 activation in PC14PE6/AS2 cells by dominant-negative Stat3 reduces VEGF expression, microvessel density, in vivo vascular permeability, and the formation of malignant ascites and MPE in animal models, all of which support the assumption that the IL-6/Stat3 pathway is important in the generation of MPE by ADCLC cells.
We found no difference in viability, cell-cycle progression, or apoptosis ratio between Stat3-positive (Vec) and Stat3-negative (S3D-8, S3D-9, and S3F) cells (data not shown). However, the abilities of colony formation in soft agar and tumor formation in nude mice (data not shown) are reduced in Stat3-negative cells. In an ascites model, dispersed tumors in peritoneal cavities were found in both Stat3-positive and -negative groups, but ascites were detected in the Stat3-positive group only. Therefore, activated Stat3 influences the generation of malignant effusion in vivo. The observation that S3D and S3F cells could develop tumor but could not form malignant ascites is consistent with the findings of other investigators. Mesiano et al. (1998) found that ascites production was completely inhibited in mice bearing intraperitoneal ovarian carcinoma tumors by treatment with a function-blocking VEGF antibody specific for human VEGF. However, intraperitoneal tumor growth was only partially inhibited. Yano et al. (2000b) showed that PC14PE6 cells (injected intravenously) induced pleural effusion in nude mice, which was significantly reduced by the treatment with a VEGF/VPF receptor tyrosine kinase inhibitor-PTK 787, whereas there was no significant change in the number of metastatic lung lesions. Taken together, these data indicate that VEGF is crucial for the production of malignant effusion but not for the tumor formation. In our lung metastasis and MPE model, grossly detectable tumors and MPE developed in the Stat3-positve group, but only microscopic tumors formed in the Stat3-negative group. The lack of MPE in the Stat3-negative group may have resulted from fewer tumor metastases developing in the lungs as well as the inferior capability of the cancer cells to generate effusion. Taken together, Stat3 activation is implicated in the formation of malignant effusions and tumor metastases in vivo.
We found elevated IL-6 and VEGF in the MPE of patients with lung cancer. We also demonstrated that Stat3 activation in tumor cells from patients with ADCLC with MPE have higher positive rates than those without MPE. Although the studies were performed in different cohorts of patients, the data support the hypothesis that the IL-6/Stat3/VEGF pathway is activated in patients with ADCLC and MPE.
In conclusion, this is the first study to report that Stat3 activation in ADCLC may contribute to its tumor formation, angiogenesis, vascular hyper-permeability, malignant effusion formation, and lung metastasis. These findings will provide novel targets for the control of ADCLC and malignant effusions.
Materials and methods

Materials
Mammalian expression plasmid for the dominant-negative mutants of Stat3, Stat3D, was kindly provided by Dr T Hirano (Nakajima et al., 1996) . The Stat3 reporter gene (pm67-Luc) and active-form Stat3 (Stat3C) plasmids were kindly provided by Dr James Darnell Jr (Bromberg et al., 1999) . AG490, LY294002, PD98059, PP1, PP2, and PP3 were obtained from Biomol International LP (Plymouth Meeting, PA, USA). Monoclonal anti-HA and b-actin antibodies were obtained from Sigma-Aldrich (St Louis, MO, USA). pStat3-Y705-and pSrc-Y416-specific antibodies were obtained from New England Biolabs (Beverly, MA, USA). Stat3, Src, and pJAK2-Y1007/1008 antibody were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Vascular endothelial growth factor antibody was obtained from Oncogene Science (Bayer HealthCare LLC, Cambridge, MA, USA). gp130 antibody was obtained from Biosource International (Camarillo, CA, USA). Interleukin-6 was purchased from SigmaAldrich Fine Chemicals (St Louis, MO, USA).
Patients and sample processing Pleural effusion samples were collected from patients with ADCLC-induced MPE and benign pleural effusions induced by CHF as previously described (Hung et al., 2003) . Briefly, each ADCLC-associated MPE was verified positive by cytological analysis or a pleural biopsy. Effusions of CHF were collected from patients with documented heart failure but without neoplastic disease. Effusions were collected in sterile tubes and centrifuged immediately at 41C. Cell-free supernatants were collected, and aliquots were stored frozen at À701C until use. Pleural effusion samples were assayed for IL-6 or VEGF using an ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Animals and models
Male or female BALB/c nude mice 6-8 weeks old were obtained from our university's Animal Center, where they were maintained in a pathogen-free environment throughout the study. Ascites model: PC14PE6/AS2 cells in suspension (1 Â 10 6 /0.1 ml) were injected into the peritoneal cavity of unanesthetized BALB/c nude mice. All the mice were killed on the day when the event of first mouse death was found. The peritoneal tumors and ascites amount in mice were evaluated. Experimental lung metastases and pleural effusion model: PC14PE6/AS2 cells in suspension (1 Â 10 6 /0.1 ml) were injected through the tail vein of BALB/c nude mice. All the mice were killed on the day when the event of first mouse death was found, and the lung lesions and pleural effusion were evaluated.
Cell lines
Cell lines NCI-H1355, H1435, H157, H1650, H460, H520, and 293T were obtained from American Type Culture Collection (ATCC; Rockville, MD, USA). The human lung adenocarcinoma, PC14PE6, cell line was kindly provided by Dr Fidler (MD Anderson Cancer Center, Houston, TX, USA). The PC14PE6/AS2 cell line was established from ascites generated by PC14PE6 in an SCID mouse.
Cell lysis
To obtain total cellular protein lysates, cells were washed twice with ice-cold PBS and lysed with 200 ml per 10-cm plate of whole-cell extract lysis buffer (Tris 50 mM pH 7.2-7.8, NP-40 1%, EDTA 2 mM, NaCl 100 mM, Na orthovanadate 10 mM, 0.1% sodium dodecyl sulfate (SDS), leupeptin (10 mg/ml), aprotinin (2 mg/ml), and phenylmethylsulfonyl fluoride 100 mM) (protease inhibitors from Roche Applied Sciences, Indianapolis, IN, USA). Lysates were cleared using centrifugation at 14 000 r.p.m. for 10 min, and protein concentration was determined using a Bradford assay (Bio-Rad, Richmond, CA, USA).
RNA extraction and semiquantitative RT-PCR Total RNA was extracted using a single-step method with TRIzol reagent (Invitrogen Corp., Carlsbad, CA, USA). For RT-PCR, first-strand cDNA was synthesized from 0.2 to 1 mg of total RNA with an oligo-dT primer and the Moloney murine leukemia virus (MMLV) reverse transcriptase (Promega, Madison, WI, USA). The sequences of PCR primers were as follows: VEGF sense primer, 5 0 -AGC TAC TGC CAT CCA ATC GC-3 0 ; VEGF antisense primer, 5 0 -GGG CGA ATC CAA TTC CAA GAG-3 0 ; b-actin sense primer, 5 0 -TGG AAT CCT GTG GCA TCC ATG AAA C-3 0 ; and b-actin antisense primer, 5 0 -TAA AAC GCA GCT CAG TAA CAG TCC G-3 0 . The PCR protocol was performed with the VEGF primers at 941C for 30 s, 551C for 30 s, and 721C for 1 min (35 cycles), followed by 721C for 10 min. The PCR protocol was performed with the b-actin primer at 941C for 30 s, 551C for 30 s, and 721C for 1 min (25 cycles), followed by 721C for 10 min.
Western blot analysis
Whole-cell extracts were boiled for 5 min with sample buffer before separation on SDS-polyacrylamide gels. The proteins were transferred to a nitrocellulose filter (Millipore, Billerica, MA, USA) in Tris-glycine buffer at 100 V for 1.5 h using an electroblotter (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA). Membranes were blocked with PBS buffer containing 5% nonfat milk before incubation with antibodies. Binding of each antibody was detected using an electrochemiluminescence kit (Amersham) according to the manufacturer's instructions.
Luciferase reporter assays
Triplicate samples of 1 Â 10 5 cells in 35-mm plates were transfected using lipofectin (GIBCO BRL, Life Technologies, Inc., Grand Island, NY, USA). pm67-Luc Stat3 reporter gene (5 mg) and b-galactosidase expression vector (0.5 mg) were cotransfected. After 16 h, the medium was changed to fresh DMEM. The cells were then incubated for 24 h, and luciferase activity was then determined in cell extracts using a luciferase assay system (Promega). b-Gal activities were also determined using a b-galactosidase enzyme assay system (Promega). Luciferase activities were then normalized with respect to b-gal activities.
Enzyme-linked immunosorbent assay for interleukin-6 Cells were plated in their respective growth media at 5 Â 10 5 cells/well in 100-mm dishes and incubated in a humidified 371C incubator in a 95% air/5% CO 2 atmosphere for 24 h. Culture medium incubated without cells served as controls. Conditioned medium was then harvested and stored at À701C. The conditioned medium was thawed and centrifuged briefly before assay for IL-6 protein using a commercially available ELISA kit (R&D Systems).
Chromatin immunoprecipitation assay PC14PE6/AS2 cells (7 Â 10 6 cells/150-mm dish) were treated with IL-6 (20 ng/ml) for 30 min, and ChIP assays were conducted as previously described (Wells et al., 2000) . Briefly, cells were crosslinked at room temperature for 10 min using 1% formaldehyde. After sonication, the resulting soluble chromatin was diluted 1:10 with dilution buffer and immunoprecipitated by anti-Stat3 antibody (Santa Cruz, CA, USA) or IgG overnight at 41C with rotation. The following day, chromatin-antibody complexes were isolated from solution by incubating them with protein G-Sepharose beads (Amersham) for 1 h at 41C with rotation. The Sepharose-bound immune complexes were washed. The immune complexes were eluted from the beads using an elution buffer (1% SDS and 0.1 M NaHCO 3 ) and then the DNA was extracted. DNA samples from ChIP preparations were analysed using PCR. The primers and probes for VEGF promoter were as follows: forward: 5 0 -TCA CTG ACT AAC CCC GGA AC-3 0 and reverse: 5 0 -GCC TGC AGG CAT CAA AGT GA-3 0 .
Immunohistochemistry
The tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 5-m-thick sections. For immunohistochemistry, the sections were deparaffinized, rehydrated, incubated with 3% H 2 O 2 in methanol for 20 min, and subjected to heat-induced antigen retrieval by boiling for 10 min in 0.01 M sodium citrate. Subsequently, the specimens were blocked with normal goat serum for 30 min and incubated for 2.5 h at room temperature with anti-phosphospecific Stat3 (Tyr705) antibody (1:100) (New England Biolabs). The immune complex was visualized using a kit (Vectastain Elite Kit; Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. The density of blood vessels in solid tumors was determined in tissue sections stained with anti-CD31 antibodies. Areas containing the highest number of capillaries and small venules were identified by scanning the tumor sections at low power ( Â 40). Individual vessels were counted in multiple 100 Â fields ( Â 10 objective and Â 10 ocular; 0.145 mm 2 /field). Five fields were counted for each case.
In vivo vascular permeability assay (Miles assay) To evaluate the bioactivity of VEGF/VPF secreted by tumor cells, we used the Miles permeability assay adapted to the mouse skin. The mice were intravenously injected with 200 ml of 0.5% Evans blue dye. After 10 min, serum-free culture supernatants of tumor cells (10 6 cells/48 h in 50 ml of MEM) were injected intradermally in several rows on the dorsal skin. After 30 min, the mice were killed, their skin removed, and the test sites were photographed.
Statistical analysis
Data were analysed using Prism4 (GraphPad Software for Science Inc., San Diego, CA, USA). Results were expressed as the mean7standard error of the mean (s.e.m.). Statistical significance was set at Po0.05. Differences between two independent groups were determined using the Mann-Whitney U-test. Differences between more than two groups were determined using one-way ANOVA-Bonferroni multiple comparisons.
